Michael A Metzger
Director; Director, Chief Executive Officer · 5 filings · Latest: Jul 8, 2026
Pyxis Oncology, Inc.
Syndax Pharmaceuticals Inc
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
SNDX | Michael A Metzger | Director, Chief Executive Officer | Jul 8, 2026 | Sale | $24.24 | 32,375 | $784.8K | 484,843 | |
SNDX | Michael A Metzger | Director, Chief Executive Officer | Jul 8, 2026 | Option Exercise | $6.38 | 32,375 | $206.6K | 517,218 | |
SNDX | MICHAEL METZGER | — | Jul 8, 2026 | Proposed Sale | $23.24 | 32,375 | $752.4K | — | |
SNDX | Michael A Metzger | Director, Chief Executive Officer | Jun 1, 2026 | Sale | $18.99 | 6,847 | $130.0K | 484,843 | |
SNDX | Metzger Michael A | — | Jun 1, 2026 | Proposed Sale | $18.99 | 6,847 | $130.0K | — | |
SNDX | Michael A Metzger | Director, Chief Executive Officer | Feb 9, 2026 | Sale | $21.03 | 17,159 | $360.8K | 491,690 | |
SNDX | Metzger Michael A | — | Feb 9, 2026 | Proposed Sale | $21.03 | 17,159 | $360.8K | — | |
SNDX | Michael A Metzger | Director, Chief Executive Officer | Feb 6, 2026 | Sale | $20.62 | 7,412 | $152.8K | 508,849 | |
SNDX | Metzger Michael A | — | Feb 6, 2026 | Proposed Sale | $20.62 | 7,412 | $152.8K | — | |
SNDX | MICHAEL METZGER | — | Sep 8, 2025 | Proposed Sale | $17.04 | 157,307 | $2.7M | — | |
SNDX | Metzger Michael A | — | Jul 16, 2025 | Proposed Sale | $9.29 | 7,534 | $70.0K | — | |
SNDX | MICHAEL METZGER | — | Mar 4, 2025 | Proposed Sale | $15.48 | 13,888 | $215.0K | — | |
SNDX | Metzger Michael A | — | Feb 10, 2025 | Proposed Sale | $15.50 | 13,288 | $206.0K | — |